Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mesterolone→

Mesterolone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1424-00-6
Molecular formula
C20H32O2
Molecular weight
304.5 g/mol
Drug class
Synthetic androgendihydrotestosterone-derived androgen receptor agonist
Mechanism of action
A 5α-dihydrotestosterone derivative that activates androgen receptors. It is not aromatised to oestrogens and has relatively limited anabolic activity compared with testosterone; clinical effects relate to androgen replacement in selected men.
Indications / reported uses
  • Treatment of androgen deficiency in adult men in countries where mesterolone is authorised.
  • Historically used in selected cases of male infertility associated with androgen deficiency; use depends on local product information and specialist assessment.

Sources: https://www.ncbi.nlm.nih.gov/mesh/68008655 · https://www.moh.gov.bh/HealthInfo/DrugDetail/318?lang=en · https://uroweb.org/guidelines/sexual-and-reproductive-health/chapter/male-hypogonadism · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mesterolone Environmental Risk Assessment (ERA) (the Mesterolone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.